Clinical Trial Search

Primary: Time-Weighted Sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug…

Primary: Glycosylated Hemoglobin (HbA1c) 6 Months After Enrollment — 8.17; 7.99; 8.44; 8.21 percentage — p=0.95

Primary: Dizziness Handicap Inventory (DHI) — 29.2; 34.9; 33.3; 32.1 score on a scale — p=0.013

Primary: Change in Annualized Relapse Rate (ARR) Between the Pre-Baseline 12-Month Period (Baseline) and Over the 12 Months Period Before the End of Study Follow-Up (2 Years)…

Primary: Rate of Adherence (Physiotherapy Session) — 7 Participants

Primary: Number of Participants With Satisfaction With Intervention Content — 28 Participants

Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants

Primary: Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14 — 24.24; 14.50 percentage of participants…

Primary: Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Day 56 — -2.25; -0.31 score on a scale — p=<0.0001

Primary: Overall Response Rate — 0.35 proportion of participants

Primary: Spherical Aberration Measurement — 0.162; 0.090; 0.017; 0.052 microns

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 [Noninferiority Analysis] — -0.51; -0.56 Percentage of HbA1c

Primary: Change in Percent Correct on Word Recognition in Quiet in Implanted Ear — 25.6 Change in percentage points

Primary: [Cohort A, B, C & D] Maximum Tolerated Dose (MTD) of Xentuzumab — 1000; 1000; 1000; 1000 milligram

Primary: Percentage of Participants Treated With Sevasemten Experiencing AEs — 100 percentage of participants